Funck, Jr. Robert E.'s Form 4 filing
Abbott Laboratories (ABT) · filed Mar 2, 2023
- Accession no.
- 0001415889-23-003907
- Filed
- Mar 2, 2023
- Trade date
- Feb 28-Mar 1, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions and 0 derivative transactions. Open-market sales total $127.3K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Funck, Jr. Robert E.CIK 0001565892 | Officer (EXECUTIVE VICE PRESIDENT) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 28, 2023 | Common shares without par value | FTax withholdingDisposed | −11,500 | $99.77 | −$1,147,355 | 219,501 | Direct | |
| Mar 1, 2023 | Common shares without par value | SSaleDisposed | −1,264 | $100.70 | −$127,284.8 | 218,237 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.